administration lactobacillus plantarum ncimb 8826 lactobacillus reuteri f275 prevent severe rti healthy mouse reduce proinflammatory cytokine expression respiratory mucosa,15 'antiinflammatory prim immunity observe peripheral blood mononuclear cell extract healthy human supplement lab4 probiotic consortium.16 vitamin c also show hinder proinflammatory cytokine response monocyte lymphocyte extract healthy adults,17 date study examine effect probiotic vitamin c combination rti preschool child objective study investigate impact probiotic consortium combination vitamin c incidence duration rtis ass associate immunological metabolic change child sixtynine healthy child 36 year attend preschool slovakia recruit study write inform consent obtain parent legal guardian prior participation study child exclude take medication immunostimulatory product form probiotic prior time enrolment sensitive xylitolsorbitol none child receive flu vaccine study period doubleblinded randomise placebocontrolled study conduct protocol approve ethical committee department health care human pharmacy trnava slovakia 16092010 register current control trial isrctn28722693 6month intervention study period child receive daily either one chewable tablet contain lab4 probiotic consortium comprise two strain lactobacillus acidophilus cul21 ncimb 30156 cul60 ncimb 30157 bifidobacterium bifidum cul20 ncimb 30153 bifidobacterium animalis subsp lactis cul34 ncimb 30172 total 1.25 × 10 colonyforming unit lactobacillus sp 1 × 10 bifidobacterium sp 0.25 × 10 50 mg vitamin c base xylitol identical look placebo tablet contain xylitol cultech ltd port talbot uk compliance assess monitor amount tablet return child examine paediatric physician background information include history allergy record body weight height measure use digital weigh measure station automatic body mass index calculation kgm seca 764 seca deutschland hamburg germany twelvehour overnight fast venous blood sample collect edtavacutainer tube plasma extract centrifugation 1200 g 10 min storage 80 °c urine sample collect first morning urination store 80 °c prior h nuclear magnetic resonance nmr analysis saliva collection child rinse mouth cold water saliva collect plastic tube store 20 °c parentsguardians complete weekly symptom diary monitor temperature runny nose sore throat cough chest wheeze earache diarrhoea vomit stomach ache absence preschool prescription antibiotic physician visit hospitalisation medication take intervention period start end study complete dieticiandesigned diet habit physical activity pattern questionnaire consist 3 question meal drink pattern 12 question intake various food 3 question relate physical activity questionnaire assess use score system summary score baseline upon completion study compare intervention period child examine paediatric physician prescheduled 2 4 6month appointment unscheduled visit result urti lrti illness 6 month blood urine saliva collect child provide saliva blood sample collection day thereby reduce active placebo group size quantification interferonγ ifnγ interleukin il10 il12p70 il13 il1β il2 il4 il5 il8 tumour necrosis factorα tnfα conduct use multispot electrochemiluminescence array msd technology accordance manufacturer 's protocol cbs cardiff university cardiff uk saliva sample centrifuge 800 g 15 min iga level assay enzymelinked immunosorbant assay e80102 bethyl laboratory montgomery al usa urine sample thaw room temperature vortexed 10 centrifuge 10 000 g 10 min supernatant transfer 96well plate use robotic system bruker rheinstetten germany 540 μl urinary sample mix 60 μl 1.5 potassium phosphate buffer ph7.4 0.1 3trimethylsilyl2,2,3,3h propionic acid sodium salt tsp 2 mm sodium azide transfer nmr tube h nmr spectrum acquire use bruker 600 mhz spectrometer brukergermany operate h frequency 600.13 mhz temperature 300 k. standard nmr pulse sequence recycle delay90°t90°t90°acquisition provide standard onedimensional h nmr spectral data 3 m mix time 10 ms. water peak suppression achieve use selective irradiation recycle delay 4 t. 90degree pulse adjust 10 μs total 32 scan collect 64 k data point spectral width 20 p.p.m eligible subject allocate 1:1 ratio two arm study accord computergenerated random sequence use block randomisation blocksize four randomisation perform study statistician contact participant participant enrol assign sequentially intervention paediatric physician allocation sequence available member research team database complete lock primary end point measure incidence duration urti lower respiratory tract infection lrti absence preschool number visit paediatric centre due rti urti symptom include sneeze sore throat cough runny block nose distinct episode time period day cover continuous display symptom separate another episode minimum 24 h. lrti confirm paediatric physician lrti duration number day physician confirm onset absence symptom secondary end point change plasma cytokine salivary iga urine metabolite parentreported measure include diarrhoea 823 loose stool 24h period vomit stomach ache pilot study formal sample size calculation primary end point analysis incidence rate ratio number episode divide number day study mean difference duration urtis lrtis absence preschool number visit paediatric centre rtis intervention period 95 confidence interval ci calculate use generalise linear model glm include treatment single predictor secondary immunological end point analyse similarly glm analysis continuous end point duration urti lrti normal distribution identity link function use glm analysis recurrence event number episode urti symptom poisson distribution log link function use posthoc covariateadjusted analysis within glm framework perform primary end point treatment study variable centre age gender body mass index covariates subgroup analysis perform gender continuous variable summarise use number observation mean s.d. whereas categorical variable summarise number percentage event analysis study end point perform per protocol analysis pp modify intentiontotreat itt population exclude participant withdraw shortly randomisation dietary habit physical exercise questionnaire data analysis perform use glm model treatment study variable baseline measurement covariate data analysis perform use sa version 9.2 sa institute inc. cary nc usa automatic phase baseline correction reference tsp signal δh 0.00 perform h nmr urinary spectrum process nmr spectral data δh 0.2510 import matlab r2012a 7.14.0.739 mathworks digitise 20 k data point resolution 0.0005 p.p.m use matlab script develop within section computational system medicine water peak region δh 4.74.9 remove owe disorder peak shape cause water suppression addition variation intensity urea signal δh 5.46.1 cause chemical exchange solvent hence region also remove probabilistic quotient normalisation perform remain spectral data order account dilution complex biological mixture principal component analysis orthogonal partial least square discriminant analysis carry unit variancescaled data simca p13.0 matlab software orthogonal partial least square regression analysis perform correlate metabolic data cytokine \<SEP>1